QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)

NVN Liquidation (NOVNQ) Competitors

$0.0008
0.00 (0.00%)
(As of 02/26/2024 ET)

NOVNQ vs. NOVN, CALA, SCPS, PBLA, KTRA, AVTX, RNAZ, GRI, PTEIQ, and SNES

Should you be buying NVN Liquidation stock or one of its competitors? The main competitors of NVN Liquidation include Novan (NOVN), Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Panbela Therapeutics (PBLA), Kintara Therapeutics (KTRA), Avalo Therapeutics (AVTX), TransCode Therapeutics (RNAZ), GRI Bio (GRI), PolarityTE (PTEIQ), and SenesTech (SNES). These companies are all part of the "medical" sector.

NVN Liquidation vs.

Novan (NASDAQ:NOVN) and NVN Liquidation (NASDAQ:NOVNQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novan$24.71M0.00-$31.31M-$1.320.00
NVN Liquidation$23.68M0.00-$31.31M-$1.320.00

Novan received 239 more outperform votes than NVN Liquidation when rated by MarketBeat users.

CompanyUnderperformOutperform
NovanOutperform Votes
239
57.45%
Underperform Votes
177
42.55%
NVN LiquidationN/AN/A

Novan has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, NVN Liquidation has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500.

In the previous week, NVN Liquidation's average media sentiment score of 0.00 equaled Novan'saverage media sentiment score.

Company Overall Sentiment
Novan Neutral
NVN Liquidation Neutral

Novan currently has a consensus target price of $8.00, indicating a potential upside of 999,900.00%. Given NVN Liquidation's higher possible upside, research analysts plainly believe Novan is more favorable than NVN Liquidation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novan
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
NVN Liquidation
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

NVN Liquidation has a net margin of 0.00% compared to NVN Liquidation's net margin of -128.61%. Novan's return on equity of 0.00% beat NVN Liquidation's return on equity.

Company Net Margins Return on Equity Return on Assets
Novan-128.61% -700.28% -39.58%
NVN Liquidation N/A N/A N/A

14.5% of Novan shares are held by institutional investors. Comparatively, 7.1% of NVN Liquidation shares are held by institutional investors. 1.3% of Novan shares are held by company insiders. Comparatively, 1.3% of NVN Liquidation shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Novan and NVN Liquidation tied by winning 5 of the 10 factors compared between the two stocks.


Get NVN Liquidation News Delivered to You Automatically

Sign up to receive the latest news and ratings for NOVNQ and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NOVNQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NOVNQ vs. The Competition

MetricNVN LiquidationPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$22,000.00$7.31B$5.09B$7.46B
Dividend YieldN/A2.81%2.86%3.87%
P/E Ratio0.0018.35250.8318.42
Price / Sales0.00966.123,418.02179.53
Price / CashN/A18.1425.3625.75
Price / Book0.004.704.574.56
Net Income-$31.31M$163.09M$111.05M$210.58M
7 Day PerformanceN/A2.85%1.85%-0.18%
1 Month PerformanceN/A10.42%9.72%3.65%
1 Year PerformanceN/A4.08%11.82%6.84%

NVN Liquidation Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NOVN
Novan
0.8556 of 5 stars
$0.01
flat
$8.00
+159,900.0%
-99.9%$140,000.00$24.71M0.0090
CALA
Calithera Biosciences
0 of 5 stars
$0.03
+66.4%
N/A-70.5%$122,000.00$9.75M0.008Analyst Report
News Coverage
SCPS
Scopus BioPharma
0 of 5 stars
$0.00
flat
N/AN/A$72,000.00N/A0.0013Gap Down
PBLA
Panbela Therapeutics
2.1795 of 5 stars
$1.11
-3.5%
$500.00
+44,945.0%
-99.8%$289,000.00N/A0.006
KTRA
Kintara Therapeutics
0.2266 of 5 stars
$0.10
flat
N/A-98.2%$325,000.00N/A-0.022Gap Down
AVTX
Avalo Therapeutics
0.0326 of 5 stars
$4.44
+4.0%
N/A-99.4%$400,000.00$18.05M-0.0120News Coverage
RNAZ
TransCode Therapeutics
1.9402 of 5 stars
$0.73
+9.0%
$480.00
+66,015.7%
-99.8%$457,000.00N/A0.0019
GRI
GRI Bio
0 of 5 stars
0.85
-12.0%
N/AN/A$549,000.00N/A-0.011Positive News
Gap Up
High Trading Volume
PTEIQ
PolarityTE
0 of 5 stars
$0.02
flat
N/AN/A$149,000.00$810,000.00-0.0142
SNES
SenesTech
3.1743 of 5 stars
$0.92
-20.0%
$3.50
+279.7%
-96.2%$278,000.00$1.20M0.0029Analyst Revision
Gap Down

Related Companies and Tools

This page (NASDAQ:NOVNQ) was last updated on 2/26/2024 by MarketBeat.com Staff